2005, a pivotal year for Axis-Shield, with strong growth and profitability

ScobieBreasley...Thanks. Anything can be considered, I thought that the inclusion of ‘key’ info for the year ahead made for quick and easy reference, point noted though.

The Trots...Most certainly not, you merely latched onto known factors (manufacturing scale up issue), and inflated/sensationalised them and then you also inferred Afinion was experiencing problems in the field with end users, no, the only ‘nuggets’ that your posts contained was the one’s normally heading down the pan!

Croasdale...Thanks for the update and your thoughts etc. The following might also be an indicator then -

INTERVIEW Axis-Shield says AFINION to be 50 mln usd product in 3-4 yrs

LONDON (AFX) - Axis-Shield PLC said that its AFINION point of care system,
which is set to be launched in non-US markets in November of this year, will be
a 50 mln usd product in 3-4 years time. -


I am sure there is also a newspaper article/interview suggesting similar.

However, what is now an interesting element going forwards, is how the inclusion of Abbott's Axsym and IMX reagents will affect the numbers further out and whether back in Sept 2004 (the date of the news item above) that was a consideration when indicating Afinion’s revenue?

BTW...Anyone care to comment on ASD's COL1A1 and Roche?

Regards, wan